+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

5-hydroxydecanoate fails to attenuate ventricular fibrillation in a conscious canine model of sudden cardiac death



5-hydroxydecanoate fails to attenuate ventricular fibrillation in a conscious canine model of sudden cardiac death



European Journal Of Pharmacology. 306(1-3): 99-106



The electrophysiologic and antifibrillatory properties of 5-hydroxydecanoate, a K-ATP channel antagonist, were studied in a conscious canine model of sudden cardiac death. After a surgically induced myocardial infarction, animals were subjected to programmed electrical stimulation to identify those at risk for sudden cardiac death. 5-Hydroxydecanoate was administered as a bolus (10 mg/kg i.v.) followed by an infusion, 10 mg/kg/h (group 1, n = 12) or 30 mg/kg bolus followed by an infusion, 30 mg/kg/h (group 2, n = 8) i.v., while vehicle treated animals received a 0.9% sodium chloride solution (group 3, n = 11). The administration of 5-hydroxydecanoate did not alter the ventricular effective refractory period or the QTc interval. Anterior wall myocardial infarcts, expressed as a percentage of the left ventricle, did not differ among groups. Infusions of 5-hydroxydecanoate did not confer significant protection from sudden cardiac death (death within 60 min of posterolateral ischemia) due to ventricular fibrillation: group 1, 50%; group 2, 38%; and group 3, 18%. The data demonstrate that a continuous infusion of 5-hydroxydecanoate (10 and 30 mg/kg/h, i.v.) does not provide protection from ischemia-induced ventricular fibrillation in the postinfarcted conscious canine.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 008017679

Download citation: RISBibTeXText

PMID: 8813621

DOI: 10.1016/0014-2999(96)00208-7


Related references

The KATP channel antagonist 5-hydroxydecanoate fails to protect against ventricular fibrillation in a conscious canine model of sudden cardiac death. FASEB Journal 9(3): A605, 1995

Tedisamil Attenuates Ventricular Fibrillation in a Conscious Canine Model of Sudden Cardiac Death. Journal of Cardiovascular Pharmacology and Therapeutics 1(4): 313-324, 1996

Tedisamil protects against ventricular fibrillation in a conscious canine model of sudden cardiac death. FASEB Journal 10(3): A33, 1996

Ventricular fibrillation in a conscious canine model of sudden cardiac death Effects of MS-551, a multiple dose regimen. FASEB Journal 8(4-5): A78, 1994

Prostacyclin on ventricular fibrillation in a conscious canine model of sudden coronary death. Naunyn-Schmiedeberg's Archives of Pharmacology 321(Suppl.): R54, 1982

Effect of flecainide acetate on ventricular tachycardia induction and ventricular fibrillation prevention in a conscious canine model of sudden death. Journal of the American College of Cardiology 7(2 Suppl. A): 84A, 1986

Prevention of ventricular fibrillation by bretylium in a conscious canine model of sudden coronary death. American Heart Association Monograph (82): IV-125, 1981

Prevention of ventricular fibrillation by bretylium in a conscious canine model of sudden coronary death. American Heart Journal 105(5): 711-717, 1983

Prevention of ventricular fibrillation by dextrorotatory sotalol in a conscious canine model of sudden coronary death. American Heart Journal 109(5 Pt 1): 949-958, 1985

Prevention of ventricular fibrillation by dextro sotalol in a conscious canine model of sudden coronary death. American Heart Journal 109(5 Part 1): 949-958, 1985

Ventricular fibrillation resulting from ischemia at a distant site in conscious canine model of sudden coronary death. American Heart Association Monograph (82): IV-218, 1981

Ventricular fibrillation in a conscious canine model of sudden coronary death prevention by chronic amiodarone therapy. American Heart Association Monograph: I-132, 1982

Failure of thromboxane synthetase inhibition to protect the postinfarcted heart against the induction of ventricular tachycardia and ventricular fibrillation in a conscious canine model of sudden coronary death. Pharmacology 37(3): 171-186, 1988

Failure of Thromboxane Synthetase Inhibition to Protect the Postinfarcted Heart against the Induction of Ventricular Tachycardia and Ventricular Fibrillation in a Conscious Canine Model of Sudden Coronary Death. Pharmacology 37(3): 171-186, 1988

Prostacyclin prevents ventricular fibrillation in a canine model of sudden cardiac death. Basic Research in Cardiology 81(1): 40-53, 1986